Biovail Suffers One-Two Punch In Wellbutrin XL Feud

Law360, New York (August 2, 2006, 12:00 AM EDT) -- In a setback for Canada’s Biovail Corp. in the ongoing legal battle over its blockbuster drug Wellbutrin XL, a federal judge on Tuesday granted Anchen Pharmaceuticals Inc. a key part of a summary judgment motion that will allow the generic maker to produce a copycat version of the antidepressant.

U.S. District Judge James V. Selna of the U.S. District Court for the Central District of California said in court documents this week that Anchen’s generic version of Wellbutrin XL, a once-daily pill used to treat depression,...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.